Vyome Holdings, Inc.

HIND

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001427570

E

weakest fifth of 370 graded peers in healthcare

rank 363 of 370; percentile 98.1; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	C/D percentile 62.4
Solvency	D/E percentile 80.5
Growth and financing	E percentile 91.8
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $6.5M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, late filer; fortress balance sh... not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Mar 18, 2026 236 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$1.60 2026-11-06; market equity $11.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 18, 2026

Lifesciences Inc. (now known as Vyome Holdings, Inc.) (the "Company") completed the merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome"). Pursuant to the Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the "Merger"). As a result of the Merger, the Company was renamed "Vyome Holdings, Inc.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 62.4						
Gross profitability	3.4%	32.3%		87.6	365	2025-12-31
Return on invested capital	not computable	9.3%				

required facts have no common fiscal period end

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(165.3%)	(6.6%)	2.4	802	2025-12-31
Gross margin stability, five years	24.6 pts	2.8 pts	97.1	242	2025-12-31
Solvency, sleeve percentile 80.5					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(50.57)	(0.37)	88.9	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
required facts have no common fiscal period end					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	1.99x	2.94x	72.1	828	2025-12-31
Growth and financing, sleeve percentile 91.8					
Revenue growth, three-year compound	(69.5%)	10.0%	97.8	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 7					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(16.5%)	2.2%	78.6	696	2025-12-31
Net share issuance, one year	6,124.2%	2.5%	98.9	630	2026-03-17

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 6124.2%
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Fortress balance sheet	cash minus debt is 11,257,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
358	Clene Inc. (CLNN)	96.7	E	dilution
359	Dare Bioscience, Inc. (DARE)	97.0	E	dilution
360	Longeveron Inc. (LGVN)	97.3	E	short runway
361	Nektar Therapeutics (NKTR)	97.6	E	dilution, short runway
362	Agenus Inc. (AGEN)	97.8	E	dilution
363	Vyome Holdings, Inc. (HIND)	98.1	E	dilution, late filer, fortress balance sheet
364	Sintx Technologies, Inc. (SINT)	98.4	E	dilution, short runway
365	Coherus Oncology, Inc. (CHRS)	98.6	E	dilution, short runway
366	Atara Biotherapeutics, Inc. (ATRA)	98.9	E	dilution, short runway

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

367	HCW Biologics Inc. (HCWB)	99.2	E	dilution, short runway, late filer, degenerate inputs, fortress balance sheet
368	PAVmed Inc. (PAVM)	99.5	E	dilution, short runway, degenerate inputs

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(68.1%)	(2.1%)	8
Distance from 52-week high	(72.4%)	(30.4%)	12
EBIT to enterprise value	(168.5%)	(1.5%)	4
Free cash flow yield	(153.3%)	(1.0%)	5
Book value to price	0.66	0.29	76
Sales to price	0.03	0.30	10
Composite equity issuance, five years	1,332.0%	20.8%	99
Relative strength against the sector, log excess return	(1.31)	(0.19)	8

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$7.9M
Operating cash flow, four quarters	-$5.6M
Months of runway	17.0
Days since last periodic filing	89 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$15,863

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$218,771	2025-12-31	2026-03-18	10-K	26-029500
2	assets	us-gaap:Assets	$6.5M	2025-12-31	2026-03-18	10-K	26-029500
3	net income	us-gaap:NetIncomeLoss	-$10.3M	2025-12-31	2026-03-18	10-K	26-029500
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$3.7M	2025-12-31	2026-03-18	10-K	26-029500
5	assets	us-gaap:Assets	$1.4M	2024-12-31	2026-03-18	10-K	26-029500
6	revenue	us-gaap:Revenues	$319,714	2025-12-31	2026-03-18	10-K	26-029500
7	gross profit	us-gaap:GrossProfit	$194,970	2024-12-31	2026-03-18	10-K	26-029500
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$8.0M	2024-12-31	2025-04-04	10-K	25-004477
9	gross profit	us-gaap:GrossProfit	$5.5M	2023-12-31	2025-04-04	10-K	25-004477
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$8.7M	2023-12-31	2025-04-04	10-K	25-004477
11	gross profit	us-gaap:GrossProfit	$6.8M	2022-12-31	2024-04-01	10-K	24-004559
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$11.2M	2022-12-31	2024-04-01	10-K	24-004559

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

13	gross profit	us-gaap:GrossProfit	$8.3M	2021-12-31	2023-04-17	10-K	23-006079
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$13.6M	2021-12-31	2023-04-17	10-K	23-006079
15	current assets	us-gaap:AssetsCurrent	$5.4M	2025-12-31	2026-03-18	10-K	26-029500
16	current liabilities	us-gaap:LiabilitiesCurrent	$2.7M	2025-12-31	2026-03-18	10-K	26-029500
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$87.6M	2025-12-31	2026-03-18	10-K	26-029500
18	operating income	us-gaap:OperatingIncomeLoss	-$10.5M	2025-12-31	2026-03-18	10-K	26-029500
19	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	$3.8M	2025-12-31	2026-03-18	10-K	26-029500
20	liabilities	us-gaap:Liabilities	$2.7M	2025-12-31	2026-03-18	10-K	26-029500
21	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$43,000	2023-12-31	2025-04-04	10-K	25-004477
22	depreciation amortization	us-gaap:Depreciation	$121,000	2023-12-31	2025-04-04	10-K	25-004477
23	operating income	us-gaap:OperatingIncomeLoss	-$15.4M	2023-12-31	2025-04-04	10-K	25-004477
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$11.3M	2023-12-31	2025-04-04	10-K	25-004477
25	income tax	us-gaap:IncomeTaxExpenseBenefit	$52,000	2023-12-31	2025-04-04	10-K	25-004477
26	current assets	us-gaap:AssetsCurrent	$10.3M	2023-12-31	2025-04-04	10-K	25-004477
27	current liabilities	us-gaap:LiabilitiesCurrent	$3.8M	2023-12-31	2025-04-04	10-K	25-004477
28	current assets	us-gaap:AssetsCurrent	$9.9M	2022-12-31	2024-04-01	10-K	24-004559
29	current liabilities	us-gaap:LiabilitiesCurrent	$7.5M	2022-12-31	2024-04-01	10-K	24-004559
30	assets	us-gaap:Assets	$10.7M	2023-12-31	2025-04-04	10-K	25-004477
31	assets	us-gaap:Assets	$11.1M	2022-12-31	2024-04-01	10-K	24-004559
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,018,528	2026-03-17	2026-03-18	10-K	26-029500
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,276,248	2025-04-02	2025-04-04	10-K	25-004477

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.